The recommendations from the workshop were just published in the medical literature: Recommendations for real-world evidence of efficacy and safety of GLP-1 agonists in Prader-Willi syndrome: Report of a workshop held by the Foundation for Prader-Willi Research and International Prader Willi Syndrome Organisation The experts agreed on the urgent need to collect detailed real-world data from individuals with PWS who are prescribed GLP-1s
Wagner says Clinical trials are an essential step in developing new medications and therapies, and the norovirus vaccine trial, part of a national study, aims to reduce the impact of the disease that sickens thousands of people every year, leading to lost work productivity, school absences, hospitalizations, and more
The human body produces GHK naturally
No procedure required
Employer coverage is rapidly expanding - 44% of large employers now cover GLP-1s for obesity, with 21% more considering coverage within three years
World Psychiatry 22 , 129149 (2023)